By the Leanova Research Team
Cover photo: Photo by cottonbro studio on Pexels (https://www.pexels.com/photo/a-doctor-talking-the-patient-7579831/), free to use under the Pexels License; lightly colour-graded and cropped for header (3:2) and wide (4:1) versions.
A year ago, choosing a weight-loss injection in India meant picking between two expensive imported brands. Today the choice is much wider and much more confusing. The semaglutide patent expired in March 2026, dozens of Indian generics arrived almost overnight, the original brands cut their prices, and social media is now full of talk about a "next-generation" drug called retatrutide.
If you are a working professional trying to work out which option makes sense for your health, schedule and budget, this guide walks through what the medicines are, what the best evidence shows, what they cost right now, and the safety questions that matter most.
The medicines, in plain words
There are really only two approved medicines in this conversation, sold under several names.
• Semaglutide copies one gut hormone, GLP-1, that helps you feel full and slows down how quickly your stomach empties. In India it is sold by Novo Nordisk as Wegovy (for weight management) and Ozempic (for type 2 diabetes), by Emcure as Poviztra, and since March 2026 by many Indian companies as generic semaglutide.[1][2]
• Tirzepatide acts on two hormones, GIP and GLP-1. In India it is sold by Eli Lilly as Mounjaro. According to Lilly India's official launch announcements after CDSCO marketing authorisation, Mounjaro is indicated as an adjunct to diet and exercise for type 2 diabetes, and for chronic weight management in adults with BMI of 30 kg/m² or greater, or BMI of 27 kg/m² or greater with at least one weight-related comorbid condition (vial launch 20 March 2025; KwikPen nationwide 12 August 2025).[3][4] Some secondary Indian pharmacy and media pages still describe Mounjaro as diabetes-only; that conflicts with Lilly India's published India indication language. Confirm the current approved uses on the product label with your doctor. There is no generic tirzepatide in India.[5]
Both are once-weekly injections. Both start at a low dose and are stepped up every four weeks to reduce side effects. Both are prescription-only medicines. Lilly India's KwikPen announcement also states that Mounjaro is not approved for cosmetic weight loss and must be used under medical supervision.[4]
What the trials show about weight loss
Average results from large trials give a useful sense of scale, but they are averages, and individual results vary a lot. These trials also used different populations, doses and durations, so the numbers are not a simple ranking of products on a pharmacy shelf.
• Semaglutide 2.4 mg (STEP 1). Adults without diabetes lost an average of 14.9% of their body weight over 68 weeks, compared with 2.4% on a dummy injection.[6]
• Tirzepatide (SURMOUNT-1). Adults without diabetes lost an average of 15.0%, 19.5% and 20.9% on the 5 mg, 10 mg and 15 mg doses over 72 weeks, compared with 3.1% on a dummy injection.[7]
• The head-to-head trial (SURMOUNT-5). In 2025, the two medicines were compared directly in 751 adults with obesity but without diabetes, each at the maximum tolerated dose (tirzepatide 10 mg or 15 mg; semaglutide 1.7 mg or 2.4 mg). After 72 weeks, average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide, and waist size fell by 18.4 cm and 13.0 cm respectively.[8] The trial was funded by Eli Lilly, was open-label (participants knew which medicine they were taking), and was run mainly in the United States.
So, on average, tirzepatide produced more weight loss in that head-to-head study. But "more on average" does not automatically mean "better for you". Many people reach their health goals with semaglutide, some cannot tolerate higher doses of either medicine, and cost matters for treatment that may continue for a long time, especially if you are paying out of pocket while working.
What they cost in India right now
Prices have moved fast this year. As a rough guide, here are maximum retail prices (MRP) reported for November 2026 from pharmacy listings and NPPA-linked pack prices. Pharmacies may sell for less, and prices change often.
• Mounjaro (tirzepatide) KwikPen: about ₹13,125 a month at the 2.5 mg starting dose, rising to about ₹25,781 a month at the 12.5 mg and 15 mg pens (each pen holds four weekly doses).[5][9]
• Wegovy (semaglutide): after Novo Nordisk's late-March / early-April 2026 price cut to compete with generics, the 0.25 mg starter FlexTouch pen is listed around ₹5,660 (about ₹1,415 a week), rising to about ₹16,400 at the 2.4 mg maintenance pen.[1][10][11]
• Ozempic (semaglutide, diabetes): about ₹5,660 to ₹9,100 a month depending on dose.[5]
• Poviztra (semaglutide): Emcure cut its starting-dose price by 55% to ₹3,999 a month from April 2026.[12]
• Generic semaglutide: more than a dozen versions launched within days of the patent expiry, with prices up to 90% lower than the original brands.[2] Reported monthly costs range roughly from about ₹1,400 to ₹8,000 depending on the product and dose.[5][11]
Two important cautions about generics. First, generic semaglutide is the same molecule as Wegovy and Ozempic, but not every generic product is approved in India for weight management; some are approved only for type 2 diabetes. Your doctor should check what a specific product is approved for. Second, remember that the medicine is only part of the cost of safe treatment. Doctor reviews, blood tests and nutrition support matter as much as the pen, especially if you need a plan you can sustain around work.
What about retatrutide?
Retatrutide is an experimental medicine from Eli Lilly that acts on three hormones: GIP, GLP-1 and glucagon. On 21 May 2026, Lilly reported topline results from its Phase 3 TRIUMPH-1 trial: in adults without diabetes, the 12 mg dose produced an average 28.3% body-weight loss over 80 weeks on the efficacy estimand (the analysis that assumes people stayed on treatment as assigned). On the treatment-regimen estimand (which includes people who stopped or used other weight-loss treatments), average loss at 12 mg was 25.0%.[13] Lilly also reported the usual stomach side effects, including nausea in 42.4% of people at the highest dose, as well as an unusual skin sensation (dysesthesia) in about one in eight at 12 mg.[13] These figures come from a company topline release; Lilly said detailed results would be presented later and published in peer-reviewed journals, so they should be read as preliminary company-reported data, not as a completed head-to-head comparison with Mounjaro or Wegovy.
But here is what matters for you today: retatrutide is not approved by any regulator anywhere in the world, including India. Lilly describes it as investigational and says it is legally available only to participants in Lilly clinical trials.[13] Indian trial sites have taken part in its research, but a trial is not a licence to sell. Vials sold online as "retatrutide" are unregulated, and in 2026 Indian investigators found it among seized products during a raid on a counterfeit weight-loss drug operation.[14] Please do not inject anything sold this way.
Safety: the side effects to know about
Semaglutide and tirzepatide share a similar side-effect profile.
• Common: nausea, vomiting, diarrhoea, constipation, reduced appetite and indigestion. These are usually mild to moderate and most likely in the first weeks after each dose increase.[8]
• Less common but serious: inflammation of the pancreas (severe tummy pain that may spread to the back), gallbladder problems, dehydration that can strain the kidneys, and low blood sugar in people also taking certain diabetes medicines.
• Who should usually avoid them: people with a personal or family history of medullary thyroid cancer or MEN2 syndrome, and anyone who is pregnant or planning a pregnancy soon.
Slow dose increases, eating smaller meals, drinking enough water and getting enough protein help many people. A doctor can also adjust the plan instead of you pushing through side effects between meetings or giving up.
Doctor-led care versus buying online
The rush of demand in India has brought a dangerous black market with it.
• In March 2026, India's drug regulator, the CDSCO, issued an advisory banning surrogate advertising and indirect promotion of GLP-1 medicines, and it later inspected 49 online pharmacy warehouses, wholesalers, retailers and slimming clinics, issuing notices for unauthorised sale, improper prescription practices and misleading marketing.[15]
• In April 2026, officials in Gurugram seized 262 suspected fake Mounjaro injections worth about ₹70 lakh, made in a residential flat and sold online. Some unapproved injections from the same operation were traced to buyers in Delhi, Hyderabad and other cities.[16]
A fake or badly stored pen may contain the wrong dose, the wrong substance, or nothing at all, and it may not be sterile. For a busy professional, the safe route is still the simple one: a prescription from a registered doctor after a proper assessment, a medicine bought from a licensed pharmacy, and regular follow-up that fits around work rather than a same-day online deal.
How a doctor helps you choose
There is no single "best" injection. A good assessment looks at:
1. Your health picture: BMI using Asian cut-offs, waist size, HbA1c, lipid profile, liver tests, BP, and conditions such as PCOS, fatty liver or sleep apnoea.
2. Your goals: how much weight loss would make a real difference to your health and day-to-day energy.
3. Your budget over time: these medicines often work best when continued, so a cost you can sustain for a year or more matters more than the cheapest first month.
4. How you tolerate the medicine: some people do well on a moderate dose, and some need to switch.
5. The plan beyond the pen: protein, strength training, sleep and follow-up blood tests that fit a desk-job week.
Frequently asked questions
Is Mounjaro better than Wegovy?
In the one head-to-head trial, tirzepatide (Mounjaro) led to more weight loss on average than semaglutide (Wegovy): 20.2% versus 13.7% over 72 weeks at maximum tolerated doses.[8] But the right choice depends on your health, how you tolerate the medicine and what you can afford long term.
Is Mounjaro approved for weight management in India?
Lilly India's official CDSCO-authorisation launch materials (March and August 2025) state that Mounjaro is indicated for chronic weight management in eligible adults with obesity or overweight plus a weight-related condition, as well as for type 2 diabetes.[3][4] Some secondary pages still say diabetes-only. Ask your doctor to confirm against the current product label; do not rely on social media or secondary pharmacy blogs alone.
Is generic semaglutide as good as Wegovy?
Generic semaglutide is the same active molecule. What you should check with your doctor is whether the specific product is approved in India for weight management, and that it comes from a licensed pharmacy.
How much does Mounjaro cost per month in India?
Reported KwikPen MRP in November 2026 ranges from about ₹13,125 a month at the starting dose to about ₹25,781 a month at the highest doses.[5][9] Prices change, so check at the time of purchase.
Can I buy retatrutide in India?
No. Retatrutide is still experimental and is not approved anywhere in the world. Anything sold under that name is unregulated.
Can I start a weight-loss injection without a doctor?
No. These are prescription-only medicines, and India's drug regulator has been acting against sales without proper prescriptions.[15] A doctor needs to check whether they are safe for you and monitor you while you take them.
Will I need to take it forever?
Not necessarily, but trials show that many people regain weight after stopping, so stopping should be planned with your doctor.
How Leanova can help
At Leanova, our registered physicians assess your health, explain your options honestly, including cost, and build a plan you can sustain around work, with regular reviews, blood tests and nutrition support. We work with patients online across India, including Hyderabad and Telangana, Delhi, Chandigarh, Bengaluru and across Maharashtra.
• WhatsApp: +91 93633 43330
• Email: care@leanova.in
• Website: leanova.in
Disclaimer: This article is for general education only and is not medical advice. It does not replace a consultation with a registered doctor. Prices quoted are reported maximum retail prices as of November 2026, shown as a guide only, and may change. Do not start, stop or change any medicine without speaking to your doctor. Individual results vary, and no treatment can guarantee a specific outcome. Semaglutide and tirzepatide are prescription medicines and can cause side effects, most commonly nausea, vomiting, diarrhoea and constipation, and less commonly more serious problems such as pancreatitis or gallbladder disease. Retatrutide is an investigational medicine that is not approved for use. Indication language for Mounjaro in India is summarised from Eli Lilly India's publicly posted launch materials citing CDSCO marketing authorisation; always confirm approved uses on the current product label with your doctor.
References
1. Reuters. Novo Nordisk cuts Ozempic, Wegovy prices in India again to fight cheaper generics. 31 March 2026. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-further-slashes-prices-ozempic-wegovy-india-better-compete-generics-2026-03-31/
2. Business Standard. Semaglutide prices crash up to 90% as 15+ generics launch in two days. March 2026. https://www.business-standard.com/industry/news/semaglutide-prices-crash-up-to-90-as-15-generics-launch-in-two-days-126032200534_1.html
3. Eli Lilly India. Lilly launches Mounjaro (tirzepatide), offering a new option for the treatment of obesity and type 2 diabetes. 20 March 2025. https://www.lilly.com/in/news/press-releases/lilly-launches-mounjaro-tirzepatide-offering-a-new-option-for-the-treatment-of-obesity-and-type-2-diabetes
4. Eli Lilly India. Lilly launches Mounjaro KwikPen (tirzepatide) to advance care for adults living with type 2 diabetes and obesity. 12 August 2025. https://www.lilly.com/in/news/press-releases/lilly-launches-mounjaro-kwikpen-tirzepatide-to-advance-care-for-adults-living-with-type-2-diabetes-and-obesity
5. PharmEasy. GLP-1 comparison: India brands, uses and costs side by side (MRPs as of November 2026). https://pharmeasy.in/glp-1/compare/
6. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
7. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
8. Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393:26-36. https://www.nejm.org/doi/full/10.1056/NEJMoa2416394
9. PharmEasy. Mounjaro price in India: MRP and monthly cost (updated November 2026). https://pharmeasy.in/glp-1/mounjaro/price/
10. PharmEasy product listing. Wegovy 0.25 mg FlexTouch (MRP ₹5,660; last updated 16 October 2026). https://pharmeasy.in/online-medicine-order/wegovy-0-25mg-flextouch-pen-of-1-5ml-injection-4485842
11. Counterfoil / NPPA Pharma Sahi Daam pack MRPs for Wegovy FlexTouch strengths (August 2026 filings; read 3 November 2026). https://counterfoil.in/medicines/brand/wegovy/
12. Emcure Pharmaceuticals. Emcure reduces Poviztra starting dose price by 55% to expand patient access. April 2026. https://www.emcure.com/wp-content/uploads/2026/04/Press-Release-Poviztra-Price-Reduction-April-2026.pdf
13. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1 topline results). 21 May 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
14. Mint. Fake Mounjaro to unapproved retatrutide: Inside India's booming weight-loss drug black market. 2026. https://www.livemint.com/news/india/fake-mounjaro-to-unapproved-retatrutide-inside-indias-booming-weight-loss-drug-black-market-11790685000027.html
15. ThePrint. As GLP-1 generics flood Indian market, drug regulator cracks down on illegal sale and misleading ads. 2026. https://theprint.in/health/as-glp-1-generics-flood-indian-market-drug-regulator-cracks-down-on-illegal-sale-and-misleading-ads/2888043/
16. The Times of India. Man who sold fake weight-loss drug masked his brand as 'Japanese'. 2026. https://timesofindia.indiatimes.com/city/gurgaon/man-who-sold-fake-weight-loss-drug-masked-his-brand-as-japanese/articleshow/130998543.cms